Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents; DETECT-OCT Trial

Trial Profile

DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents; DETECT-OCT Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2019

At a glance

  • Drugs Everolimus (Primary) ; Antiplatelets; Umirolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms DETECT-OCT
  • Most Recent Events

    • 19 Mar 2019 Status changed from recruiting to completed.
    • 14 Nov 2018 Results (n=386) evaluating early follow-up findings of Significant Stent Malapposition (SSM) presented at the 91st Annual Scientific Sessions of the American Heart Association.
    • 21 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top